Bharat Biotech’s Covid nasal vaccine gets regulator’s nod for holding phase 2, 3 trials

The first nasal COVID-19 vaccine developed by Bharat Biotech has got regulatory approval for phase second and third trials. This is the first of its kind COVID-19 jab to undergo human clinical trials in India.   The Department of Biotechnology said the phase one Clinical trial has been completed in the age groups ranging  18 to 60 years. The Company reports that the doses of the vaccine administered to healthy volunteers in this phase has been well tolerated and no serious adverse events have been reported. Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies.  The Department said the vaccine was able to elicit high level of neutralizing antibodies in animal studies.

Secretary, Department of Biotechnology, Dr. Renu Swarup, said that the Department through Mission COVID Suraksha is committed to development of safe and efficacious COVID-19 vaccines.


The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies